FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials: 2-Day In-Person Seminar by Ex-FDA Official

Venue:

FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials: 2-Day In-Person Seminar by Ex-FDA Official

Tampa,  

Time:

From  2018-12-06 13:30:00  to  2018-12-07 21:00:00
Event Description
Because a phase 1 clinical trial initially introduces an investigational new drug into human subjects, appropriate CGMP help ensure subject safety. It is important to implement quality control (QC) principles to the manufacture of phase 1 investigational drugs (i.e., interpreting and implementing CGMP consistent with good scientific methodology), which foster CGMP activities that are more appropriate for phase 1 clinical trials, improve the quality of phase 1 investigational drugs, and facilitate the initiation of investigational clinical trials in humans while continuing to protect trial subjects. The following steps to establish the appropriate manufacturing environment for phase 1 investigational drugs should be taken: A comprehensive and systematic evaluation of the manufacturing setting (i.e., product environment, equipment, process, personnel, materials) to identify potential hazards Appropriate actions prior to and during manufacturing to eliminate or mitigate potential hazards to safeguard the quality of the phase 1 investigational drug Review the FDA recommendations and requirements for implementing a compliant program for the phase 1 clinical program. The following topics will be discussed to provide the foundation and basis for advancing drugs into clinical development from research and providing required information to the FDA regarding these products. Overview of Good Manufacturing Practices GMP Requirements for a Phase 1 Study   Personnel QC Function Facility and Equipment Control of components, containers and closures Manufacturing & Records Laboratory Controls Vendor selection & management Process Validation Special Considerations Multi-product facilities Biologics Sterile products Combination products Providing relevant information in the IND application Course benefit: This workshop will review the current regulations, guidance documents for early stage manufacturing and GMPs in detail. Regulatory strategies and logistical considerations for early development stage product, including vendor selection and management, stability, labeling, and documentation requirements will also be reviewed and explored.  Who will Benefit: Directors Manager Supervisors Lead workers in Regulatory Affairs Quality Assurance and Quality Control Workers who will prepare GMP documents for early phase products Workers who will review GMP documents for early phase products Speaker: Peggy J. BerryMBA, RAC,President & CEO, Synergy Consulting (Ex-FDA Official) Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2015, she was Vice President of Regulatory Affairs at Insmed (2/2015-5/2015) where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin (3/2009-2/2014). She has also held a variety of senior level positions at Dyax (5/2006-3/2009), MGI Pharma (now Eisai; 7/2005-5/2006), AstraZeneca (10/2001-7/2005), and Dey Pharma (now Mylan; 12/1997-10/2001). She has also held Regulatory Affairs roles within two clinical contract research organizations (ILEX Oncology and Cato Research Ltd; 1992-1997) and has worked in review divisions at the FDA (1985-1992). In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book "Choosing the Right Regulatory Career" (RAPS, MD) and author of the 2011 book "Communication & Negotiation" (RAPS, MD). For Registration - http://www.complianceonline.com/fda-gmp-expectations-phase-i-first-in-man-clinical-trials-iso-9001-2015-qms-cmc-seminar-training-80366SEM-prdsm?channel=eventbrite              Note: Use coupon code REFERRAL10 > and get 10% off on registration.